scholarly journals Cost effectiveness analysis of universal varicella vaccination in the Russian Federation

2021 ◽  
Vol 13 (3) ◽  
pp. 114-119
Author(s):  
A. V. Rudakova ◽  
S. M. Kharit ◽  
I. V. Babachenko ◽  
L. N. Konovalova ◽  
S. V. Rychkova ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Healthcare System ◽  
Russian Federation ◽  
Weighted Average ◽  
Indirect Costs ◽  
Epidemiological Data ◽  
Varicella Vaccination ◽  
The Russian Federation ◽  
Sick Children ◽  
The Cost

Varicella is a significant burden on society and the healthcare system.Objective: to analyze the cost effectiveness of universal vaccination of children against varicella.Material and methods. The analysis was carried out from the perspective of the healthcare system and societal perspective, based on epidemiological data for the Russian Federation. The effect was taken into account only in the vaccinated population. The time horizon of the study is 10 years. The amount of direct medical costs for treatment of varicella was calculated based on the rates of compulsory medical insurance in St. Petersburg in 2020. The cost of drug therapy in outpatient settings was calculated based on the weighted average retail price of prescribed drugs. The analysis of direct nonmedical and indirect costs was carried out taking into account statistical data on the Russian Federation and duration of temporary disability of family members of sick children. Costs and quality-adjusted life expectancy were discounted by 3.5% per year.Results. The average cost due to the disease in the Russian Federation is 43,139 rubles / patient, of which 8,5% is direct cost. Vaccination of 100,000 children will prevent 38,551 cases of varicella in 10 years. When analyzing from a social perspective, vaccination provides a reduction in costs compared to no vaccination, and the savings will amount to 10.1 thousand rubles per 1 vaccinated person.If vaccination coverage is 90%, taking into account the fact that the cohort of children in the Russian Federation at the age of 1 year is about 1.9 million people, the cost of vaccination will amount to about 8.1 billion rubles annually. At the same time, already 6 years after vaccination, the volume of averted budgetary costs will exceed the costs of vaccination.Conclusion. Universal varicella vaccination of children will reduce the incidence of the disease and reduce the budget costs associated with this disease.

scholarly journals INFLUENZA VACCINATION OF CHILDREN OF PRESCHOOL AGE IN THE RUSSIAN FEDERATION: COST-EFFECTIVENESS OF QUADRIVALENT VACCINE

2019 ◽  
Vol 11 (1) ◽  
pp. 92-97
Author(s):  
A. V. Rudakova ◽  
D. M. Danilenko ◽  
D. A. Lioznov ◽  
L. S. Karpova ◽  
S. M. Kharit ◽  
...  
Keyword(s):  
Health Care ◽  
Cost Effectiveness ◽  
Societal Perspective ◽  
Russian Federation ◽  
Epidemiological Data ◽  
Preschool Age ◽  
Quadrivalent Vaccine ◽  
Influenza B ◽  
The Russian Federation ◽  
The Cost

According to requirements of WHO, the trivalent influenza vaccines (TIV) have to contain antigens of two influenza A strains (A/H1N1, A/H3N2) and one influenza B strain which can be presented by antigens of a virus of lineages Yamagata or Victoria. In a season of 2017/2018 the discrepancy of the vaccinal and circulating influenza B strains was noted that caused decrease in effectiveness of vaccination, especially at children’s age when the frequency of detection of influenza B is higher, than in other age groups. Now in the Russian Federation it is registered, in addition to TIV, quadrivalent vaccine (QIV) manufactured in the Russian Federation and including antigens of influenza B viruses of the two lineages.The purpose of work was assessment of the cost-effectiveness of QIV in comparison with TIV at children of preschool age on the basis of epidemiological data on the Russian Federation for a season of 2017/2018.Material and methods. The analysis was carried out by a modeling method from a health care system and societal perspective taking into account epidemiological data on the Russian Federation and the European data on effectiveness of TIV at citizens of various age. Indirect effect of vaccination was not considered. The cost of the TIV and QIV (Grippol plus and Grippol quadrivalent, respectively) corresponded to the registered price including VAT.Results. The analysis showed that use QIV instead of TIV for children of preschool age in an epidemiological season of 2017/2018 would allow to increase quantity of the prevented influenza cases by 17.1%. The prevented indirect costs exceed the prevented direct medical costs. The incremental cost-effectiveness ratio (ICER) is 1042.65-1093.7 thousand rubles/QALY in the analysis from the health care system perspective and 124.50-267.91 thousand rubles/QALY in the analysis from the societal perspective.Conclusions. Vaccination against influenza of children of preschool age in the Russian Federation in a season of 2017/2018 with quadrivalent vaccine would allow to increase significantly the number of the prevented cases of disease and could be considered as economically highly effective intervention. Reduction of vaccine price less, than for 5% in comparison with the registered price would allow to avoid completely additional budget burden.

scholarly journals Evaluation of the Cost-Effectiveness of Vaccination of Children with 5-valent Vaccine against Rotavirus Infection in the Russian Federation

2017 ◽  
Vol 14 (6) ◽  
pp. 501-507 ◽  
Author(s):  
Alla V. Rudakova ◽  
Susanna M. Kharit ◽  
Aleksandr T. Podkolzin ◽  
Aleksandr N. Uskov ◽  
Yurii V. Lobzin
Keyword(s):  
Cost Effectiveness ◽  
Russian Federation ◽  
Rotavirus Infection ◽  
The Russian Federation ◽  
The Cost

scholarly journals Pharmacoeconomic aspects of bronchial asthma therapy: real clinical practice

2018 ◽  
pp. 60-68 ◽  
Author(s):  
A. S. Belevsky ◽  
A. A. Zaitsev
Keyword(s):  
Russian Federation ◽  
Indirect Costs ◽  
Direct Costs ◽  
Gross Regional Product ◽  
Permanent Disability ◽  
Alternative Drug ◽  
The Russian Federation ◽  
Socioeconomic Burden ◽  
Regional Product ◽  
The Cost

According to official statistics, over 1.5 million people have BA in the Russian Federation. Direct costs associated with the treatment of BA in the Russian Federation amount to 8.5 billion rubles. The socioeconomic burden of BA put on society, along with temporary and permanent disability, is caused by not only direct, but also indirect costs, as well as costs associated with payments for temporary disability, which leads to a decrease in GDP and GRP (internal gross regional product). The pharmacoeconomic comparison of two alternative drug technologies in the studied groups showed a reasonable opportunity to transfer patients to the drugs that have alternatives produced within the country, confirming that the cost per efficiency unit in using Formisonide-Native and SalticasoneNative is lower than that of drugs produced by a foreign pharmaceutical company (Symbicort Turbuhaler and Seretide Multidisk)

Cost-effectiveness of measures against rabies

2020 ◽  
Vol 1 (12) ◽  
pp. 78-83
Author(s):  
K. M. Abramov ◽  
◽  
O. V. Liseykina ◽  
I. K. Abramova ◽  
◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Russian Federation ◽  
Economic Effectiveness ◽  
Moscow Region ◽  
The Russian Federation ◽  
The Cost ◽  
Rabies Vaccination

The article presents material on current problems of rabies vaccination: the epizootic situation of rabies in the Russian Federation is considered, the analysis of the dynamics of the number of cases of animal rabies, the population's appeal for anti-rabies care is given. Based on data on preventive rabies vaccination in the Moscow region and the cost of such measures, the economic effectiveness of anti-rabies measures is evaluated.

scholarly journals Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies

2018 ◽  
Vol 11 (3) ◽  
pp. 13-22 ◽  
Author(s):  
T. S. Teptsova ◽  
T. P. Bezdenezhnyh ◽  
V. K. Fedyaeva ◽  
N. Z Musina ◽  
G. R. Hachatryan ◽  
...  
Keyword(s):  
Health Care ◽  
Cost Effectiveness ◽  
Willingness To Pay ◽  
Health Care System ◽  
Russian Federation ◽  
Threshold Value ◽  
Medical Technologies ◽  
The Russian Federation ◽  
The Cost ◽  
Care System

The aim was to develop a methodology for determining the willingness to pay threshold (WTPT) and its upper limit value within the Russian health care system.Materials and methods. WTPT was calculated based on the shadow budget price (i. e. determining the WTPT by the suppling party). This method is an empirical assessment of the cost-effectiveness threshold that reflects the utmost productivity of the health care system, as determined from the relationship between changes in healthcare expenditure and health outcomes achieved. The state’s willingness to pay for improving their citizens’ healthcare was evaluated considering the population of the Russian Federation, mortality and life expectancy in different age and gender groups, as well as the volume of government spending. The cost of disability-adjusted life-year prevented (DALY) and the cost of quality-adjusted life-year saved (QALY) were determined by the suppling party, that is, they reflect the cost the state is willing to pay for improving the health of their population under conditions of limited budget. The described approach considers the performance of the country’s healthcare system over a certain period and the costs incurred in functioning of the system.Results. As part of this study, it was found that the cost of one additionally prevented DALY would be 313,878.21 rubles, and the cost of one additionally saved QALY – 365,060.31 rubles.Conclusion. The WTPT for medical technologies in the Russian Federation, determined by estimating the shadow budget price will amount to 313,878.21 rubles for one prevented DALY and 365 060,31 rubles for one saved QALY. With regard to clinical and economic analysis, medical technologies with the incremental cost-effectiveness indicator not exceeding the one calculated in this study can be seen as cost-effective. The obtained threshold value is a recommendation. A medical technology can be approved even with a WTPT higher than the recommended level, because this specific technology may have additional  advantages other than WTPT when compared with the reference technologies. 

scholarly journals Cost-effectiveness of meningococcal vaccination of infants in the Russian Federation

2021 ◽  
Vol 13 (4) ◽  
pp. 113-120
Author(s):  
A. V. Rudakova ◽  
A. A. Vilnits ◽  
S. M. Kharit ◽  
Yu. V. Lobzin
Keyword(s):  
Cost Effectiveness ◽  
Life Expectancy ◽  
Incremental Cost ◽  
Russian Federation ◽  
Base Case ◽  
Average Lifetime ◽  
Social Perspective ◽  
The Social ◽  
The Russian Federation ◽  
The Cost

Generalized forms of invasive meningococcal desease (IMD) are very dangerous because they have a high mortality rate.The aim of the work was to assess the cost-effectiveness of meningococcal vaccination of infants with the 4-valent MenACWY-D conjugate vaccine in the Russian Federation.Material and methods. Cost-effectiveness analysis based on epidemiological data for the Russian Federation was carried out by a modeling method with a horizon of 80 years from the position of the healthcare system and taking into account the social perspective. Vaccination costs were calculated on the basis of the registered price of the vaccine, including VAT, the costs of GFMI therapy and patient rehabilitation – based on the compulsory medical insurance tariffs in St. Petersburg for 2021. Indirect costs due to temporary disability of patients’ parents, disability of patients and premature death were estimated by the lost GDP. In the base case, costs were discounted by 3,5% per year, life expectancy – by 1,5% per year.Results. Given the assumptions made, the average lifetime burden of a child’s illness is 17,556 million rubles. (no discounting). In the base case, the incremental cost per LYG from the payer perspective – 7,821 million rubles, and from the social perspective – 3,328 million rubles. Incremental cost per QALY – 5,350 million rubles and 2,277 million rubles, respectively. The most important factors that have a significant impact on the cost-effectiveness of vaccination are the incidence of IMD, the price of the vaccine, and the value of the discounting of costs and life expectancy.Conclusions. Given the assumptions made, meningococcal vaccination of infants with 4-valent meningococcal vaccine can be considered as a viable option. 

scholarly journals Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis

2021 ◽  
Vol 14 (2) ◽  
pp. 116-123
Author(s):  
A. V. Rudakova ◽  
D. G. Tolkacheva ◽  
V. D. Sokolova
Keyword(s):  
Cost Effectiveness ◽  
Healthcare System ◽  
Time Horizon ◽  
Impact Analysis ◽  
Budget Impact ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Effectiveness Analysis ◽  
The Russian Federation ◽  
The Cost

Objective: to perform cost-effectiveness analysis of the treatment for adult patients with psoriatic arthritis (PsA) with a Russian interleukin- 17А inhibitor netakimab in comparison with other biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) and to evaluate the influence of the inclusion of netakimab in the therapy for PsA on the budget of the Russian healthcare system.Material and methods. The evaluation of cost-effectiveness was performed from the position of the Russian healthcare system for patients with moderate and severe PsA. The evaluation was performed based on the results of the network meta-analysis of the randomized clinical studies. The criterion of clinical effectiveness included the changes in the condition of the joints by the criteria of the American College of Rheumatology (ACR20, ACR50, and ACR70) and changes in skin symptoms by the index of the prevalence and severity of psoriasis (PASI 75 and PASI 90) with a recalculation into quality-adjusted life-year (QALY). The time horizon of the cost-effectiveness analysis was 2 years. The calculation was based on the registered prices and VAT. If there was an original drug and a biosimilar registered on the pharmaceutical market, the calculation was based on the median of the registered prices. The budget impact analysis of the influence of netakimab inclusion in the therapy for patients with PsA was performed considering the structure of the prescription of bDMARDs and tsDMARDs that was determined in the pharmaco-epidemiological study conducted in the Russian Federation in 2020. The analysis was performed for patients that received medication by the scheme of reimbursement. The time horizon of the study was 3 years old.Results. In the base-case analysis, the cost-effectiveness ratio for netakimab was 1.210 mln rub/QALY (by 66.2–88.5% lower than in cases when comparison drugs were used). The budget impact analysis showed that the inclusion of netakimab in the therapy for PsA could reduce the costs by 376.60 mln rub (21.1%). Considering budget saving, the number of additional patients that can be treated will increase by 26.7% within 3 years.Conclusion. Netakimab is characterized by higher cost-effectiveness in comparison with other bDMARDs (adalimumab, golimumab, guselkumab, ixekizumab, infliximab, secukinumab, ustekinumab, certolizumab pegol, etanercept) and tsDMARDs (apremilast, tofacitinib) prescribed in the Russian Federation for patients with PsA. The inclusion of netakimab in the therapy for PsA will reduce the financial burden on the healthcare system.

Medical and economic analysis of the consequences of expanding the drug supply program for patients with chronic obstructive pulmonary disease in the Russian Federation

2019 ◽  
pp. 53-61
Author(s):  
Andrei Georgievich Maliavin ◽  
Alana Viktorovna Dzanaeva ◽  
Maria Vladimirovna Avxentyeva ◽  
Sergei Lvovich Babak
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Russian Federation ◽  
Chronic Obstructive ◽  
Outpatient Basis ◽  
Basic Drug ◽  
Obstructive Pulmonary Disease ◽  
Basic Therapy ◽  
The Russian Federation ◽  
The Cost ◽  
Drug Provision

Purpose of the study. Healthcare budget impact analysis in the Russian Federation of providing adult patients with chronic obstructive pulmonary disease (COPD) with basic therapy for outpatient treatment. Material and methods. The hypothesis of reducing costs for the treatment of exacerbations of COPD was tested while providing all patients with basic therapy on an outpatient basis. The model calculates the direct medical costs of drug provision and treatment of exacerbations in patients with COPD in the current situation and when all patients with COPD are covered with basic therapy as part of a program of preferential drug provision. The simulation period is 1 year. The analysis does not take into account social losses associated with disability, payment of disability certificates, reduced labor productivity and mortality. Results. The cost of providing all patients with COPD with the recommended basic drug therapy on an outpatient basis is substantially offset by a decrease in the cost of treating exacerbations: drug costs should increase by 14.1 billion rubles compared with the current situation, while the cost of providing medical care to patients with exacerbations is reduced by 9.7 billion rubles. As a result, the difference in direct medical costs, or the necessary additional investments, is 4.4 billion rubles. The price of drugs used for basic therapy has the greatest impact on the size of the required additional investments. Conclusion. Providing all patients with COPD with the recommended basic drug therapy on an outpatient basis, we can expect a decrease in the number of moderate exacerbations per year by 14.7% and severe exacerbations by 31.2%. Taking into account not only medical, but also socio-economic costs can not only offset additional investments, but also demonstrate significant savings. When implementing a pilot project of preferential drug provision for patients with COPD in a specific region of the Russian Federation, it is possible to reduce the cost of purchasing medicines when forming a municipal order.

Sign in / Sign up

Export Citation Format

Share Document